Fresenius Kabi and TQ Therapeutics recently announced a new strategic agreement to advance Cell Therapy Technology. This collaboration combines the expertise of both firms to improve the manufacturing of life-saving treatments. The partnership is centered on leveraging the use of the Fresenius Kabi Cue Cell Processing System. This technology will help to make processes simpler to prepare cells for use by patients. Both companies aim to make these advanced medical therapies more accessible to people worldwide.
Optimizing Manufacturing for Better Patient Outcomes
The deal supports the development of TQ Therapeutics’ internal pipeline and its manufacturing capabilities. Using quality Cell Therapy Technology, the companies are able to isolate T cells in less than two hours with automation that ensures safety and quality standards in final products. Furthermore, the agreement allows for faster production timelines for critical oncology treatments. Efficient processes are essential for scaling up the delivery of these personalized medicines.
“By integrating TQ Therapeutics’ novel selection technology into our Cue system, our aim is to improve manufacturing success,” said Saurabh Bhasin, Head of Portfolio at Fresenius Kabi. “These steps are vital toward supporting the advancement of cell therapies.”
TQ Therapeutics will integrate these automated systems into its clinical and commercial production workflows. This move helps the company maintain a competitive edge in the rapidly growing biotechnology sector. Modern equipment allows for more consistent results across different batches of medicine.
“This agreement with Fresenius Kabi allows us to bring our proprietary technology to a broader audience,” said Christian Eckert, CEO of TQ Therapeutics. “We are creating a novel value proposition for scaling next-generation cell therapies.”
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
